These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now. If you like shopping for high-yield dividend stocks, the past couple of years have been more than a little frustrating. A buoyant stock market has pushed the average yield of stocks in the S&P 500 down to an unattractive 1.3% at recent prices. But not every stock has seen its yield sink. Western Union (WU -0.25%) and Royalty Pharma (RPRX 0.07%) have seen their stocks fall over the past ...

NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath. "We are pleased to again partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, as we launch Yor ...

Solskin On 08/08/2024, Royalty Pharma plc (NASDAQ:RPRX) presented its Q2 earnings. Following a solid Q1, the company raised its 2024 outlook, with Portfolio Receipts expected to achieve $2.7/2.75 billion results. We positively view this announcement; however, today, we decided to focus on an ongoing downside. Downside Protection In our initiation of coverage, we reported how the Vertex franchise is one of the most significant portfolio receipt contributors. In detail, we explained: The cystic fibrosis franc ...

Solskin Introduction Since I last covered Royalty Pharma (NASDAQ:RPRX) back in January last year, the company has been an underperformer returning a -10% return while the market has gone in the opposite direction proportionally. At the time, my investment thesis was based upon three main points: 1. Royalty Pharma has a track record of compounding value. 2. The company has a durable competitive advantage in the biopharma royalty space. 3. The future outlook for the company's growth is looking better driven b ...

Royalty Pharma plc (NASDAQ:RPRX) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head of Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Chris Hite – Executive Vice President, Vice Chairman Terry Coyne – Executive Vice President, Chief Financial Officer Conference Call Participants Chris Shibutani – Goldman Sachs Hardik Pa ...

ROYALTY PHARMA ROYALTY PHARMA Royalty Pharma plc Q2 2024 Financial Results August 8, 2024 2 Forward Looking Statements & Non-GAAP Measures This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the dat ...

Royalty Pharma (RPRX) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 1.05%. A quarter ago, it was expected that this company would post earnings of $0.96 per share when it actually produced earnings of $0.98, delivering a surprise of 2.08%. Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...

Exhibit 99.1 LTY PHARMA ROYALTY PHARMA REPORTS SECOND QUARTER 2024 RESULTS • Portfolio Receipts growth of 12% to $608 million; Royalty Receipts growth of 11% • Net cash provided by operating activities of $658 million • Raising full year 2024 guidance: Portfolio Receipts expected to be $2,700 to $2,775 million NEW YORK, NY, August 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. "We delivere ...

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. About Royalty Pharma The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any ci ...